New imaging method aims to sharpen brain tumor diagnosis
NCT ID NCT07211360
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test whether combining PET scans with amino acid tracers and MRI can more accurately diagnose brain tumors and tell if they are growing or just reacting to treatment. Researchers will follow 270 adults with primary or secondary brain tumors, comparing the new imaging method to standard care. The goal is to improve diagnostic accuracy without adding extra procedures beyond routine practice.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could improve how doctors tell whether a brain tumor is growing or just reacting to treatment, leading to more accurate diagnoses.
- What could go wrong
- This is an observational study, not a treatment trial. It only tests imaging accuracy, so it won't directly improve outcomes. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 270 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2025
An estimate. Start dates often move.
- Expected to finish
-
Sep 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
adult individuals affected by primary and secondary brain tumors.
- Ages
-
18 to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 18-99. 2. Diagnosis of primary or secondary brain tumors. 3. Development of suspected lesions on MRI following treatment, with dimensions greater than one centimeter. 4. Ability to undergo PET/MRI imaging sessions. 5. Availability of clinical and follow-up data for correlation with imaging findings 6. Signed informed consent from the patient Exclusion Criteria: .Patients under 18 years of age. 2.Absence of a confirmed diagnosis of primary or secondary brain tumors. 3.Lesions on MRI with dimensions smaller than one centimeter. 4.Inability to undergo PET/MRI imaging sessions (e.g., due to medical conditions such as pregnancy, allergies to contrast agents, or presence of incompatible implants or devices) 5.Unavailability of clinical and follow-up data for correlation with imaging findings. 6.Patients who are unable or unwilling to provide signed informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Primary and secondary brain tumors are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.